Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more
Gentian Diagnostics AS (GENT) - Net Assets
Latest net assets as of December 2025: Nkr204.96 Million NOK
Based on the latest financial reports, Gentian Diagnostics AS (GENT) has net assets worth Nkr204.96 Million NOK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr258.54 Million) and total liabilities (Nkr53.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr204.96 Million |
| % of Total Assets | 79.28% |
| Annual Growth Rate | 49.69% |
| 5-Year Change | 17.28% |
| 10-Year Change | 77.39% |
| Growth Volatility | 330.89 |
Gentian Diagnostics AS - Net Assets Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gentian Diagnostics AS (2013–2025)
The table below shows the annual net assets of Gentian Diagnostics AS from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr204.96 Million | +5.62% |
| 2024-12-31 | Nkr194.05 Million | +32.33% |
| 2023-12-31 | Nkr146.64 Million | -4.89% |
| 2022-12-31 | Nkr154.17 Million | -11.78% |
| 2021-12-31 | Nkr174.77 Million | -10.18% |
| 2020-12-31 | Nkr194.58 Million | -6.56% |
| 2019-12-31 | Nkr208.24 Million | -15.31% |
| 2018-12-31 | Nkr245.87 Million | +25.14% |
| 2017-12-31 | Nkr196.48 Million | +70.05% |
| 2016-12-31 | Nkr115.54 Million | +21.54% |
| 2015-12-31 | Nkr95.06 Million | +1185.51% |
| 2014-12-31 | Nkr7.39 Million | +356.50% |
| 2013-12-31 | Nkr1.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gentian Diagnostics AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11435534900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr319.57 Million | 155.92% |
| Total Equity | Nkr204.96 Million | 100.00% |
Gentian Diagnostics AS Competitors by Market Cap
The table below lists competitors of Gentian Diagnostics AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ambika Cotton Mills Limited
NSE:AMBIKCO
|
$40.48 Million |
|
Hong Leong Capital Bhd
KLSE:5274
|
$40.48 Million |
|
Payton Planar Magnetics Ltd
BR:PAY
|
$40.49 Million |
|
Joyce Corporation Ltd
AU:JYC
|
$40.49 Million |
|
ICC Holdings Inc
NASDAQ:ICCH
|
$40.47 Million |
|
Vistin Pharma ASA
OL:VISTN
|
$40.47 Million |
|
Aprogen KIC Inc
KO:007460
|
$40.47 Million |
|
SDN Company. Ltd
KQ:099220
|
$40.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gentian Diagnostics AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 194,050,000 to 204,957,000, a change of 10,907,000 (5.6%).
- Net income of 13,256,000 contributed positively to equity growth.
- Dividend payments of 6,169,000 reduced retained earnings.
- Other comprehensive income increased equity by 890,000.
- Other factors increased equity by 2,930,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr13.26 Million | +6.47% |
| Dividends Paid | Nkr6.17 Million | -3.01% |
| Other Comprehensive Income | Nkr890.00K | +0.43% |
| Other Changes | Nkr2.93 Million | +1.43% |
| Total Change | Nkr- | 5.62% |
Book Value vs Market Value Analysis
This analysis compares Gentian Diagnostics AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 271.62x to 2.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Nkr0.15 | Nkr39.50 | x |
| 2014-12-31 | Nkr0.66 | Nkr39.50 | x |
| 2015-12-31 | Nkr8.53 | Nkr39.50 | x |
| 2016-12-31 | Nkr10.37 | Nkr39.50 | x |
| 2017-12-31 | Nkr14.04 | Nkr39.50 | x |
| 2018-12-31 | Nkr15.97 | Nkr39.50 | x |
| 2019-12-31 | Nkr13.52 | Nkr39.50 | x |
| 2020-12-31 | Nkr12.63 | Nkr39.50 | x |
| 2021-12-31 | Nkr11.34 | Nkr39.50 | x |
| 2022-12-31 | Nkr10.00 | Nkr39.50 | x |
| 2023-12-31 | Nkr9.51 | Nkr39.50 | x |
| 2024-12-31 | Nkr12.31 | Nkr39.50 | x |
| 2025-12-31 | Nkr13.29 | Nkr39.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gentian Diagnostics AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.47%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.51%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.26x
- Recent ROE (6.47%) is above the historical average (-3.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 53.95% | 3.82% | 1.62x | 8.75x | Nkr712.00K |
| 2014 | -39.33% | -11.85% | 1.27x | 2.61x | Nkr-3.65 Million |
| 2015 | -3.39% | -12.59% | 0.26x | 1.05x | Nkr-12.73 Million |
| 2016 | -7.73% | -28.89% | 0.25x | 1.06x | Nkr-20.48 Million |
| 2017 | -7.72% | -43.36% | 0.17x | 1.04x | Nkr-34.82 Million |
| 2018 | -8.05% | -42.94% | 0.18x | 1.05x | Nkr-44.39 Million |
| 2019 | -19.14% | -83.12% | 0.21x | 1.09x | Nkr-60.68 Million |
| 2020 | -8.80% | -25.03% | 0.29x | 1.21x | Nkr-36.57 Million |
| 2021 | -14.19% | -29.83% | 0.39x | 1.21x | Nkr-42.27 Million |
| 2022 | -15.57% | -23.61% | 0.54x | 1.22x | Nkr-39.42 Million |
| 2023 | -7.26% | -7.82% | 0.75x | 1.23x | Nkr-25.31 Million |
| 2024 | 23.34% | 29.78% | 0.66x | 1.18x | Nkr25.89 Million |
| 2025 | 6.47% | 7.51% | 0.68x | 1.26x | Nkr-7.24 Million |
Industry Comparison
This section compares Gentian Diagnostics AS's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $83,313,369
- Average return on equity (ROE) among peers: -189.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gentian Diagnostics AS (GENT) | Nkr204.96 Million | 53.95% | 0.26x | $40.48 Million |
| Lifecare AS (LIFE) | $1.69 Million | -444.70% | 0.35x | $407.52K |
| Medistim ASA (MEDI) | $236.86 Million | 29.68% | 0.42x | $229.18 Million |
| Observe Medical Asa (OBSRV) | $11.39 Million | -152.45% | 4.62x | $1.80 Million |